DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?
Definium Therapeutics (DFTX) and Compass Pathways (CMPS) are in focus due to a White House push to accelerate psychedelic therapy research. Both companies are developing late-stage psychedelic therapies for psychiatric conditions. DFTX has a 62% upside with a $36.67 price target, while CMPS has a 227% upside with a $21.75 target. Both companies welcomed the executive order and highlighted their ongoing clinical trials.
How this was made
The 30-second read
Why it matters
Policy could compress FDA review timelines, creating a catalyst for companies with late‑stage candidates.
Market read
Both DFTX and CMPS stand to benefit from faster regulatory pathways and federal funding, likely driving short‑term price moves.
What to watch
Funding allocation details and timeline for FDA review remain uncertain; trial outcomes still pending.
Background
White House executive order allocates $50 M to psychedelic research and urges agencies to speed approvals.
Ticker impact
Executive order to accelerate psychedelic therapy research gives DFTX regulatory head‑start and $50 M federal funding, boosting its late‑stage LSD drug DT120.
Short‑term upside of 5‑10% on news day, medium‑term upside if trial data de‑risk.
Policy change is concrete, first‑report, and directly benefits DFTX’s pipeline.
Executive order also benefits Compass Pathways’ psilocybin therapy COMP360, supporting its regulatory timeline and market expectations.
Potential 5‑12% rally as investors reassess valuation.
Policy shift is a fresh catalyst for CMPS’s late‑stage program.
Market effects
Accelerates the entire psychedelic‑therapy sector, likely lifting peer valuations.
U.S. biotech and mental‑health drug space sees heightened investor interest.
Sets a precedent for other countries to consider similar fast‑track pathways.
Counterpoint
Regulatory fast‑track may face political backlash or implementation delays, limiting upside.
Key entities
- Government OfficialDonald Trump
Signed the executive order.
- Health SecretaryRobert F. Kennedy Jr.
Commented on the initiative.
